DiaMedica Therapeutics Inc. (DMAC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, DMAC scores 44 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows. Fundamental Cash Engine scores 7 of 20, reflecting an ROIC of -35% and an FCF yield of -5.67%, which signals that the business is currently consuming rather than generating cash. Whale 13F Flow scores 15 of 20, indicating institutional accumulation and options positioning that is comparatively the strongest pillar. Insider Conviction scores 3 of 20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar in the rating. Macro Regime Fit scores 9 of 20 with a Beta of 1.0 and noted sector sensitivity. Forensic Balance Sheet scores 10 of 20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the practical implication is that the upside case rests on institutional interest and the pipeline catalysts in the news wire rather than on current cash generation or insider conviction. Valuation cannot be anchored to earnings because P/E and EV/EBITDA are not available in source data, and the company reports zero revenue and negative operating income in each reported period. The rating frames the stock as a higher-risk, catalyst-dependent name whose near-term direction depends on whether trial milestones translate into sustained capital inflows.

Per the recent news and catalysts section, the wire contains six items, each tied to DMAC. The most significant risk-flagged item is a report that DiaMedica reached a patient enrollment milestone for a Phase 2/3 trial of DM199 in acute ischemic stroke, marked RED under the RISK WATCH label. Other items, labeled MARKET WIRE with YELLOW status, include reports that the company reached 200 patients in its pivotal stroke trial, a webinar scheduled to present early results from two groups in a pregnancy trial on Nov. 24, and general seasonal return and price-action commentary from aggregator sources. The news wire contains no proprietary signals, and the Butterfly Supply-Chain Graph reports no supply-chain links, per its section.

• What are the company's revenue-generating arrangements, if any, given reported revenue of $0.0M across all periods?
• What is the debt position, since the debt line is N/A in every reported period?
• What is the cash runway implied by FY 2025 cash of $15.6M against FCF of $-29.1M?
• What are the trial milestones and timelines for DM199, and what is the nature of the RED-flagged enrollment item?
• What is the reason for the absence of analyst coverage and institutional holder data in the source set?